Lee Kwan Yong, Hwang Byung-Hee, Lim Sungmin, Kim Chan Jun, Choo Eun-Ho, Lee Seung Hoon, Kim Jin-Jin, Choi Ik Jun, Oh Gyu Chul, Yang In-Ho, Yoo Ki Dong, Chung Wook Sung, Ahn Youngkeun, Jeong Myung Ho, Chang Kiyuk
Cardiology Division, Cardiovascular Center, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul 06591, Korea.
Cardiology Division, Cardiovascular Center, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Uijeonbu 11765, Korea.
J Clin Med. 2022 Aug 18;11(16):4853. doi: 10.3390/jcm11164853.
This study aimed to investigate the relationship between a complex percutaneous coronary intervention (C-PCI) and long-term clinical outcomes in the AMI cohort. A total of 10,329 patients were categorized into the C-PCI and non-C-PCI groups. The primary ischemic endpoint was a composite of major adverse cardiac events (MACEs, cardiac death, myocardial infarction, stent thrombosis and revascularization). The primary bleeding endpoint was the risk of overt bleeding (BARC 2, 3 or 5). The median follow-up duration was 4.9 (2.97, 7.16) years. The risks of MACEs and bleeding were significantly higher in the C-PCI group (hazard ratio (HR): 1.72; 95% confidence interval (CI): 1.60 to 1.85; p < 0.001; and HR: 1.32; 95% CI: 1.17 to 1.50; p < 0.001, respectively). After propensity score matching, compared to the non-C-PCI group, the adjusted MACE rate in C-PCI remained significantly higher (p < 0.001), but no significant interaction (p = 0.273) was observed for bleeding. Significant differences in overt bleeding were observed only within the first three months (p = 0.024). The MACEs were consistently higher in the C-PCI group with or without severe comorbid conditions (p < 0.001 for both). Patients with AMI who undergo C-PCI experience worse long-term ischemic outcomes after successful PCI, regardless of the presence of severe comorbidities.
本研究旨在调查急性心肌梗死(AMI)队列中复杂经皮冠状动脉介入治疗(C-PCI)与长期临床结局之间的关系。总共10329例患者被分为C-PCI组和非C-PCI组。主要缺血终点是主要不良心脏事件(MACE,包括心源性死亡、心肌梗死、支架血栓形成和血运重建)的复合终点。主要出血终点是明显出血(BARC 2、3或5型)的风险。中位随访时间为4.9(2.97,7.16)年。C-PCI组的MACE和出血风险显著更高(风险比(HR):1.72;95%置信区间(CI):1.60至1.85;p<0.001;以及HR:1.32;95%CI:1.17至1.50;p<0.001)。倾向评分匹配后,与非C-PCI组相比,C-PCI组调整后的MACE发生率仍显著更高(p<0.001),但在出血方面未观察到显著交互作用(p=0.273)。仅在头三个月内观察到明显出血的显著差异(p=0.024)。无论有无严重合并症,C-PCI组的MACE发生率始终更高(两者p均<0.001)。接受C-PCI的AMI患者在PCI成功后经历更差的长期缺血结局,无论是否存在严重合并症。